Lilly Foundayo FDA Approval Fuels GLP-1 Race
Lilly Foundayo FDA approval clears an oral GLP-1 that will ship via LillyDirect with low advertised pricing, accelerating access and pressuring rivals.
KEY TAKEAWAYS
- FDA approved Foundayo under the CNPV after a 50-day review.
- LillyDirect shipping starts April 6, 2026 with $25 monthly and $149 self-pay pricing.
- ATTAIN-1 highest dose produced 27.3-pound (12.4%) mean weight loss at 72 weeks.
HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX
Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.
Eli Lilly and Company said on April 1, 2026, that the FDA approved Foundayo, marking the Lilly Foundayo FDA approval under the Commissioner's National Priority Voucher program and clearing the way for shipping via LillyDirect, sharpening competition with Novo Nordisk.
Approval and Trial Support
The FDA approved Foundayo (orforglipron), a once-daily oral small-molecule GLP-1 receptor agonist for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity. The approval came under the Commissioner's National Priority Voucher (CNPV) program after a 50-day review. Introduced in June 2025, the CNPV pilot granted its fifth approval with Foundayo, the first new molecular entity cleared under the program and the fastest NME decision since 2002.
The decision was based on two Phase 3 randomized trials, including the ATTAIN-1 study. In ATTAIN-1, adults on the highest 36-milligram dose lost an average of 27.3 pounds (12.4%) at 72 weeks, compared with 2.2 pounds (0.9%) for placebo. Among all trial completers, the regimen produced a mean loss of 25 pounds (11.1%) versus 5.3 pounds (2.1%) on placebo. Treated patients also showed improvements in waist circumference, non-HDL cholesterol, triglycerides, and systolic blood pressure.
The approved label carries a boxed warning for thyroid C-cell tumors and contraindicates use in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2. The most common adverse events were nausea, vomiting, and diarrhea. Trial data showed no liver-safety signals.
FDA Commissioner Martin Makary said, "This approval demonstrates what the FDA can achieve when we eliminate delays and prioritize fast and thorough work from the agency and industry partners."
Launch Pricing and Competition
Foundayo is an oral GLP-1 weight-loss pill taken once daily without food or water restrictions. It is indicated for adults with obesity or overweight plus at least one weight-related comorbidity and is intended to be used alongside a reduced-calorie diet and increased physical activity.
Prescriptions are accepted immediately through LillyDirect, which offers free home delivery. Shipments begin April 6, 2026. The company plans to expand availability through retail pharmacies and telehealth channels.
Foundayo pricing starts at $25 per month for commercially covered patients using a savings card. The self-pay cash price is $149 per month. The drug is expected to be eligible for Medicare Part D with an estimated $50 monthly copay beginning July 1, 2026.
Foundayo is the second oral GLP-1 to gain U.S. clearance after Novo Nordisk's oral Wegovy, approved in December 2025. As a small-molecule oral agent, Foundayo is easier to manufacture than peptide injectables. Lilly has submitted orforglipron for weight-management and type 2 diabetes applications in more than 40 countries and plans launches after approvals. These moves position the product to scale access and intensify competition with injectables and Novo Nordisk.
